Category: Eli
-
Where Will Eli Lilly Be in 5 Years?
•
It is difficult to argue with the types of results Eli Lily (NYSE: LLY) It has been produced over the past five years. The company was one of the best drug giants, leaving its shares the broader market in dust. Some may argue that it is too late for Eli…
-
Viking obesity drug to rival Eli Lilly’s: report (NASDAQ:VKTX)
•
Carolina Rhoda/iStock via Getty Images Eli Lilly (NYSE:LLYPopular obesity treatment Zepbound could face direct competition from Viking TherapeuticsNASDAQ:VKTX), with the latter expected to launch its flagship weight loss product VK2735 within the next few years, according to data analytics firm GlobalData. He said this week. The prediction comes after the…
-
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters
•
(Reuters) – Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug developer Morphek surged 76% to $56.15 premarket after Lilly’s offer…
-
New Alzheimer’s drug treatment from Eli Lillly wins FDA approval
•
Eli Lilly & Co. has won U.S. approval for an Alzheimer’s treatment, the second drug to slow the progression of the brain-robbing disease that affects 6 million Americans. It’s a huge win for Lilly and its investors, who have been eagerly awaiting the drug since it hit the market. show…
-
UK Planning Laws Hinder Investment, Warns Eli Lilly CEO
•
The head of the world’s largest drugs company has criticised the UK’s planning system, claiming it stifles investment. Dave Ricks, chief executive of Eli Lilly, a maker of obesity drugs, said current planning processes in the UK were a major barrier to building factories quickly, unlike in the US and…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
Eli Azur wins battle for Tamar Petroleum board after NeoGames exit
•
Israeli businessman Eli Azor was busy last week with the success of the vote on the formation of the board of directors of Tamar Petroleum (TASE: TMRP). On Wall Street, Azur and his partners completed the sale of online gambling company NeoGames (Nasdaq: NGMS) to Australian gaming and betting company…
-
Denmark’s Novo Nordisk expects 27% sales surge this year but faces price pressure for weight loss drug Wegovy amid Eli Lilly competition
•
Novo Nordisk A/S raised its earnings forecast as the drugmaker now ships five times more introductory doses of the weight-loss drug Wegovy in the US than at the end of last year. More than 25,000 patients are now starting treatment each week in the United States, CEO Lars Frørgaard Jørgensen…